Evidence map›Paper›PMID 31161320›Full record

ArticleAnalytical and bioanalytical chemistry2019

Measurement of microRNA with isothermal DNA amplification on fully automated immunoassay analyzers.

Makoto Komori, Ken Komiya, Takuma Shirakawa, Takamitsu J Morikawa, Toru Yoshimura

Abstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Ultrasound-Enhanced Chemiluminescence for Bioimaging.Frontiers in bioengineering and biotechnology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Makoto KomoriResearch and Development, Abbott Japan Co. Ltd, 278 Matsuhidai, Matsudo, Chiba, 270-2214, Japan. makoto.komori@abbott.com.
Ken KomiyaSchool of Computing, Tokyo Institute of Technology, J2-51, 4259, Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.
Takuma ShirakawaResearch and Development, Abbott Japan Co. Ltd, 278 Matsuhidai, Matsudo, Chiba, 270-2214, Japan.
Takamitsu J MorikawaResearch and Development, Abbott Japan Co. Ltd, 278 Matsuhidai, Matsudo, Chiba, 270-2214, Japan.
Toru YoshimuraResearch and Development, Abbott Japan Co. Ltd, 278 Matsuhidai, Matsudo, Chiba, 270-2214, Japan.

Funding

Adaptable and Seamless Technology Transfer Program through Target-Driven R and D AS2531277PJapan Agency for Medical Research and Development > Adaptable and Seamless Technology Transfer Program through Target-Driven R and D 17im0302430
6 · The paper itself

Abstract

MicroRNAs (miRNAs) in a blood sample are usually measured by quantitative reverse transcription PCR (qRT-PCR), microarray, and next-generation sequencing (NGS) which requires time-consuming pre-treatment, manual operation, and a stand-alone instrument. To overcome these disadvantages, miRNA testing has been developed using the automated analyzers routinely used in clinical laboratories. An isothermal DNA amplification reaction was adapted to a fully automated immunoassay analyzer that conducts extraction, amplification, and detection processes at 37 °C in 44 min. In a reaction vessel, a pre-designed single-stranded signal DNA was amplified in the presence of miRNA, using DNA templates, DNA polymerase, and nicking endonuclease. Then, the amplified signal DNA was hybridized by one DNA probe attached to a magnetic particle and another DNA probe labeled with acridinium ester. After the chemiluminescence reaction, luminescence intensity was automatically measured. The automated assays of cancer-related miRNAs were implemented on the analyzer with throughput of 66 tests per hour. In the assays with one-step amplification, three miRNAs (miR-21-5p, miR-18a-5p, and miR-500a-3p) at concentrations lower than 100 fM were automatically detected and the cross reactivity for miR-21-5p with fifteen similar miRNAs was not higher than 0.02%. In the assay with two-step amplification, detection sensitivity and amplification rate for miR-21-5p were 3 fM and 103-fold, respectively. The coefficient of variations (CVs) in the measurement at the target concentrations from 5 fM to 1000 pM were less than 8%. Furthermore, we also achieved automated nucleic acid detection in human serum. The proposed fully automated miRNA assays showed high sensitivity, low cross reactivity, and reproducibility suitable for clinical use. Graphical abstract.

Indexed as

AutomationHumansImmunoassayLuminescenceMicroRNAsNucleic Acid Amplification TechniquesMicroRNAsAutomated immunoassay analyzerCancer diagnostic markerChemiluminescence microparticle assayIsothermal DNA amplificationMicroRNA measurement

Identifiers

PMID31161320
PMCPMC6595071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.